ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1

Completed

• Conditions: Atrial Fibrillation

• Registration Number: NCT02569528
• Lead Sponsor: Duke University

Brief Summary

The goal of this study is to learn about the patient and provider perceptions, priorities, preferences, and willingness to use/prescribe anticoagulation as a stroke prevention therapy in patients with atrial fibrillation. Qualitative interviews will be performed with atrial fibrillation patients and providers caring for atrial fibrillation patients. The investigators want to understand the factors that influence decision-making about anticoagulation medications, and to gain insight into patients' and providers' knowledge of the risk of stroke and bleeding associated with oral anticoagulation. This feedback will help provide better education to providers caring for patients with atrial fibrillation and better care to patients with atrial fibrillation by developing tools to optimize the appropriate use of oral anticoagulation for patients with atrial fibrillation.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10
• Study First Submitted: 2015-10-05
• Study First Submitted QC: 2015-10-05
• Study First Posted: 2015-10-06
• Status Verified: 2016-08
• Primary Completion: 2017-03-02
• Study Completion: 2017-03-02
• Last Update Submitted: 2017-05-03
• Last Update Posted: 2017-05-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

1. adult patient age 18 or older;
2. English speaking;
3. diagnosed atrial fibrillation;
4. at least 1 risk factor for congestive heart failure, hypertension, age, diabetes, stroke (CHADS2) or 2 risk factors for CHADS2 with vascular disease, age, and sex (CHADS2-VASc) ;
5. no documented cognitive impairment per the medical record;
6. not being prescribed an oral anticoagulant

Provider Inclusion Criteria:

1. physician at one of the study sites treating patients diagnosed with atrial fibrillation

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Perceptions of using anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview	one hour	Each telephone interview (data collection time point) will be approximately one hour

Secondary Outcome Measures

Name	Time	Method
Willingness to use anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview	one hour	Each telephone interview (data collection time point) will be approximately one hour
priorities for using anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview	one hour	Each telephone interview (data collection time point) will be approximately one hour
preferences for using anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview	one hour	Each telephone interview (data collection time point) will be approximately one hour

Trial Locations

Locations (1)

Duke University Health System; 🇺🇸 Durham, North Carolina, United States